Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani

Clin Mol Hepatol. 2023;29(1):135-145. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0181

View: 1459 Download: 181 Citations: 4

Editorial

Non-invasive tests-based risk stratification: Baveno VII and beyond

Georg Semmler, Mathias Jachs, Mattias Mandorfer

Clin Mol Hepatol. 2023;29(1):105-109. Published online November 23, 2022

DOI: https://doi.org/10.3350/cmh.2022.0361

View: 586 Download: 45 Citation: 1

The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(1):102-104. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0353

View: 552 Download: 69

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 1581 Download: 266

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 1341 Download: 131 Citations: 2

Wnt signaling in liver regeneration, disease, and cancer

Gengyi Zou, Jae-Il Park

Clin Mol Hepatol. 2023;29(1):33-50. Published online July 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0058

View: 1582 Download: 128

Management of refractory ascites

Florence Wong

Clin Mol Hepatol. 2023;29(1):16-32. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0104

View: 1772 Download: 322

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection

Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller

Clin Mol Hepatol. 2023;29(1):1-15. Published online April 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0017

View: 5536 Download: 86

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 1402 Download: 91

Letter to the Editor

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(4):933-934. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0267

View: 1018 Download: 43

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies

Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung

Clin Mol Hepatol. 2022;28(4):931-932. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0259

View: 1066 Download: 68 Citation: 1

Original Article

Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus

Daxian Wu, Qunfang Rao, Zhongyang Xie, Xiaoqing Zhu, Yuanmei Che, Jian Wu, Hainv Gao, Jingyu Zhang, Zhouhua Hou, Xiaoyu Cheng, Zeyu Sun

Clin Mol Hepatol. 2022;28(4):912-925. Published online July 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0121

View: 1432 Download: 112

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2022;28(4):890-911. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0087

View: 1963 Download: 123 Citations: 3

Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis

Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun

Clin Mol Hepatol. 2022;28(4):876-889. Published online September 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0231

View: 1142 Download: 92 Citations: 2

Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease

Won Sohn, Danbee Kang, Minwoong Kang, Eliseo Guallar, Juhee Cho, Yong-Han Paik

Clin Mol Hepatol. 2022;28(4):851-863. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0037

View: 1725 Download: 97 Citations: 3

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 2392 Download: 195 Citations: 3

The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2022;28(4):814-826. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0099

View: 1797 Download: 130 Citations: 5

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 948 Download: 37

Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2022;28(4):802-805. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0249

View: 994 Download: 49 Citations: 2

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 2515 Download: 317 Citations: 13

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 6265	The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology
Viewed By 5153	Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Viewed By 4837	A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective
Viewed By 2880	KASL clinical practice guidelines for management of chronic hepatitis B
Viewed By 2667	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Cited By 61	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 34	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 33	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 27	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 27	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Search